Back

A global view: the rationale for aggresive LDL lowering

26 August 2017 (11:01 - 11:22)
Organised by:
Congress Presentation Part of: PCSK9 inhibition - cholesterol reduction and beyond Lipids (Epidemiology and Prevention) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Steven E Nissen

Cleveland Clinic Hospital, Cleveland (United States of America)

3 More presentations in this session

Presentation thumbnail
Cholesterol metabolism and the role of PCSK9
Professor S. Nicholls (Melbourne, AU)
Slides Video
Presentation thumbnail
Show me the data: clinical efficacy, safety and indications of PCSK9 inhibition
Professor J. Jukema (Leiden, NL)
Slides Video
Presentation thumbnail
Are there effects of PCSK9 inhibitors beyond cholesterol lowering?
Professor B. Cariou (Nantes, FR)
Slides Video

Access the full session

Session thumbnail
PCSK9 inhibition - cholesterol reduction and beyond

The Event

Event poster

ESC Congress 2017

26 August 2017 11:01 CET
You may be interested in
thumbnail
Webinar
LDL-C reduction postACS: strike early and strike strong
15 November 2021
thumbnail
Congress Presentation
NATURE-LEGACY: Long term legacy benefit of Lowering LDL and SBP
1 September 2025
thumbnail
Congress Session
Optimising cholesterol levels through dietary interventions: key strategies and evidence
23 June 2023
thumbnail
Congress Presentation
LDL treatment-years: a new paradigm for cardiovascular risk reduction
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources